Perceval sutureless aortic valve replacement after ascending aortic replacement

Yajima, Satoshi; Satoh, Ayaka; Sekiya, Naosumi; Yamazaki, Sachiko; Uemura, Hisashi; Tanaka, Hiroe; Yamamura, Mitsuhiro; Sakaguchi, Taichi

doi:10.1002/ccr3.5126

Cited by 2 publications

(4 citation statements)

References 4 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 44 Several small case series also support the feasibility and safety of SUAVR with concomitant mitral or tricuspid valve surgery. 45 – 49 Hanedan et al lend further support for SUAVR in this patient population, reporting significantly better valvular hemodynamics and a trend toward increased survival in patients undergoing SUAVR with concomitant procedures versus SAVR with concomitant procedures. 50 Although direct comparisons to SUAVR without concomitant procedures are required, SUAVR appears to offer an advantage for high-risk patients requiring multiple cardiac procedures.…”

Section: Resultsmentioning

confidence: 84%

The Perceval Sutureless Bioprosthetic Aortic Valve: Evolution of Surgical Valve Technology

Fialka,

EL-Andari,

Wang

et al. 2024

Innovations�(Phila)

View full text Add to dashboard Cite

Objective: The surgical treatment of aortic stenosis continues to evolve, and sutureless aortic valve replacement (SUAVR) is an emerging technology. With the Perceval S (Corcym, London, UK) as the only true sutureless valve on the market, the objective of this review is to analyze the current literature on Perceval S. Focusing on valve design and deployment as well as applications of the technology for challenging pathology, clinical outcomes are assessed, including a comparison with transcatheter AVR (TAVR). Methods: PubMed and MEDLINE were searched by 3 authors for studies analyzing SUAVR from inception to May 19, 2023. Results: SUAVR facilitates minimally invasive surgery and offers an alternative strategy for patients with small aortic annuli. It also has a time-saving advantage for patients who require complex operations. SUAVR results in excellent long-term morbidity, mortality, durability, and hemodynamic function. In comparison with conventional surgical AVR (SAVR), SUAVR does have a greater risk of postoperative pacemaker implantation; however, increasing user experience and refinements in implantation technique have contributed to reductions in this outcome. SUAVR results in morbidity and mortality that is similar to rapid-deployment AVR. Midterm outcomes are superior to TAVR; however, further robust investigation into all of these comparisons is ultimately necessary. Conclusions: SUAVR bridges the gap in technology between SAVR and TAVR. The application of this exciting technology will undoubtedly grow in the coming years, during which additional investigation is paramount to optimize preoperative planning, valve deployment, and reintervention strategies.

show abstract

Section: Resultsmentioning

confidence: 84%

The Perceval Sutureless Bioprosthetic Aortic Valve: Evolution of Surgical Valve Technology

Fialka,

EL-Andari,

Wang

et al. 2024

Innovations�(Phila)

View full text Add to dashboard Cite

show abstract

“…One way of possibly reducing the likelihood of these events is by strictly obliging the manufacturer's preoperative echo-Doppler aortic root evaluation recommendations (a patient is suitable if the ratio between the diameter of the STJ and the annular diameter is ≤1.3). 21 As mentioned, in seven cases (3.5%), reimplantation was necessary, either due to paravalvular leaks found in the intraoperative transesophageal echocardiography (four cases with subsequent aortic cross-clamping) or initial misplacement (three cases). The valve is infolded using two forceps at two opposite sites of the superior part of the stent and approximating them toward the center at the same time (known as the "x-movement" technique).…”

Section: Discussionmentioning

confidence: 91%

“…The Perceval® valve was successfully implanted in 98.99% as in two cases (2/198 = 1.01%) conversion to conventional bioprosthesis was required due to valve migration. One way of possibly reducing the likelihood of these events is by strictly obliging the manufacturer's preoperative echo‐Doppler aortic root evaluation recommendations (a patient is suitable if the ratio between the diameter of the STJ and the annular diameter is ≤1.3) 21 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Sutureless bioprosthesis for aortic valve replacement: Surgical and clinical outcomes

Ferreira

Rua

Sena

et al. 2022

Journal of Cardiac Surgery

View full text Add to dashboard Cite

Background Aortic valve stenosis is the most common adult valve disease in industrialized countries. The aging population and the increase in comorbidities urge the development of safer alternatives to the current surgical treatment. Sutureless bioprosthesis has shown promising results, especially in complex procedures and in patients requiring concomitant surgeries. Objectives Assess the clinical and hemodynamic performance, safety, and durability of the Perceval® prosthetic valve. Methods This single‐center retrospective longitudinal cohort study collected data from all adult patients with aortic valve disease who underwent aortic valve replacement with a Perceval® prosthetic valve between February 2015 and October 2020. Of the 196 patients included (mean age 77.20 ± 5.08 years; 45.4% female; mean EuroSCORE II 2.91 ± 2.20%), the majority had aortic stenosis. Results Overall mean cross‐clamp and cardiopulmonary bypass times were 33.31 ± 14.09 min and 45.55 ± 19.04 min, respectively. Mean intensive care unit and hospital stay were 3.32 ± 3.24 days and 7.70 ± 5.82 days, respectively. Procedural success was 98.99%, as two explants occurred. Four valves were reimplanted due to intraoperative misplacement. Mean transvalvular gradients were 7.82 ± 3.62 mmHg. Pacemaker implantation occurred in 12.8% of patients, new‐onset atrial fibrillation in 21.9% and renal replacement support was necessary for 3.1%. Early mortality was 2.0%. We report no structural valve deterioration, strokes, or endocarditis, and one successfully treated valve thrombosis. Conclusions Our study confirms the excellent clinical and hemodynamic performance and safety of a truly sutureless aortic valve, up to a 5‐year follow‐up. These results were consistent in isolated and concomitant interventions, solidifying this device as a viable option for the treatment of isolated aortic valve disease.

show abstract

Perceval sutureless aortic valve replacement after ascending aortic replacement

Abstract: This is an open access article under the terms of the Creat ive Commo ns Attri bution-NonCo mmercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Cited by 2 publications

References 4 publications

The Perceval Sutureless Bioprosthetic Aortic Valve: Evolution of Surgical Valve Technology

The Perceval Sutureless Bioprosthetic Aortic Valve: Evolution of Surgical Valve Technology

Sutureless bioprosthesis for aortic valve replacement: Surgical and clinical outcomes

Contact Info

Product

Resources

About